Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials
Authors:
- Stephen R. MarderSMStephen R. Marder
- Robert D. McQuadeRMRobert D. McQuade
- Elyse StockESElyse Stock
- Stephen KaplitaSKStephen Kaplita
- Ronald MarcusRMRonald Marcus
- Allan Z. SaffermanASAllan Z. Safferman
- Anutosh SahaASAnutosh Saha
- Mirza AliMAMirza Ali
- Taro IwamotoTITaro Iwamoto
- 1 June 2003
- journal article
- research article
- Published by Elsevier in Schizophrenia Research
- Vol. 61 (2-3) , 123-136
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden DeathAmerican Journal of Psychiatry, 2001
- Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: Results of an open‐label multicenter study in JapanPsychiatry and Clinical Neurosciences, 2001
- Bodyweight Gain with Atypical AntipsychoticsDrug Safety, 2001
- Network interactions in schizophrenia — therapeutic implicationsBrain Research Reviews, 2000
- Weight GainJournal of Clinical Psychopharmacology, 1999
- Neuroleptic-induced hyperprolactinemiaSchizophrenia Research, 1999
- Towards the improvement of complianceInternational Clinical Psychopharmacology, 1997
- Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trialsJournal of Psychopharmacology, 1997
- Motor and mental aspects of acute extrapyramidal syndromesActa Psychiatrica Scandinavica, 1994
- Biochemical Findings of Negative Symptoms in Schizophrenia and Their Putative Relevance to Pharmacological TreatmentNeuropsychobiology, 1994